Author: Hansel, K; Zangrilli, A; Bianchi, L; Peris, K; Chiricozzi, A; Offidani, A; Diotallevi, F; Fargnoli, M C; Esposito, M; Amerio, P; Gualdi, G; Bianchi, L; Stingeni, L
Title: A 52-week update of a multicenter real-life experience on effectiveness and safety of risankizumab in psoriasis. Cord-id: 021po7fb Document date: 2021_9_12
ID: 021po7fb
Snippet: The long-term efficacy and safety of the IL-23 inhibitor risankizumab, has been demonstrated in clinical trials, and only in a few real-world studies. We recently reported an Italian multicentre 16-week real-life experience in 57 adult patients with moderate-to-severe psoriasis treated with risankizumab. Herein, we report an extension analysis of our study beyond 16 weeks, collecting data on effectiveness of risankizumab on psoriasis characteristics (PASI, PGA, DLQI, NRS itch, NRS pain) after 36
Document: The long-term efficacy and safety of the IL-23 inhibitor risankizumab, has been demonstrated in clinical trials, and only in a few real-world studies. We recently reported an Italian multicentre 16-week real-life experience in 57 adult patients with moderate-to-severe psoriasis treated with risankizumab. Herein, we report an extension analysis of our study beyond 16 weeks, collecting data on effectiveness of risankizumab on psoriasis characteristics (PASI, PGA, DLQI, NRS itch, NRS pain) after 36 and 52 week treatment.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date